Skip to content

Omeros OMER Enterprise value

Enterprise value at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$787.38M+114%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.14B+874%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Vor Biopharma logo
Vor BiopharmaVOR
$704.51M+902%
Annexon logo
AnnexonANNX
$676M+373%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's enterprise value?
Omeros (OMER) reported enterprise value of $1.22B in Q4 2025.
How has Omeros's enterprise value changed year-over-year?
Omeros's enterprise value increased by 107.6% year-over-year, from $588.58M to $1.22B.
What is the long-term trend for Omeros's enterprise value?
Over 5 years (2020 to 2025), Omeros's enterprise value has grown at a 6.1% compound annual growth rate (CAGR), from $907.01M to $1.22B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.